This review focuses on the most contentious issue. It examines the complex environment of patents, licensing, and ethical ownership in bioprinting, the most sophisticated application. By questioning the nature of intellectual property, the article questions the current system, which has the potential to stifle future innovation and restrict patient access. The rhetorical function is to establish the ideals of the curation by demonstrating an awareness of the key, current policy impediments that jeopardize the promise indicated in prior sources.